What is it about?
Adalimumab is a potentially effective treatment for intestinal Behçet’s disease in Japanese patients who are refractory to conventional treatments.
Featured Image
Why is it important?
This is the first trial showing the efficacy of adalimumab in patients with intestinal Behçet’s disease
Perspectives
Adalimumab is a potentially effective treatment for all type of Behçet’s disease icluding neuro and vascular tyoes.
Dr Satoshi Tanida
Nagoya City university
Read the Original
This page is a summary of: Adalimumab for the Treatment of Japanese Patients With Intestinal Behçet’s Disease, Clinical Gastroenterology and Hepatology, May 2015, Elsevier,
DOI: 10.1016/j.cgh.2014.08.042.
You can read the full text:
Contributors
The following have contributed to this page
